{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:25:58Z","timestamp":1778631958003,"version":"3.51.4"},"reference-count":24,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":728,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Blood Cancer"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1002\/pbc.24623","type":"journal-article","created":{"date-parts":[[2013,9,3]],"date-time":"2013-09-03T16:21:36Z","timestamp":1378225296000},"page":"297-301","source":"Crossref","is-referenced-by-count":30,"title":["Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: A prospectively randomized cross-over study"],"prefix":"10.1002","volume":"61","author":[{"given":"Torben Stamm","family":"Mikkelsen","sequence":"first","affiliation":[{"name":"Department of Pediatric Oncology; Aarhus University Hospital; Aarhus Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aissata Diop","family":"Mamoudou","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology; Aarhus University Hospital; Aarhus Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruta","family":"Tuckuviene","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology; Aalborg University Hospital; Aalborg Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peder Skov","family":"Wehner","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology; Odense University Hospital; Odense Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Schroeder","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology; Aarhus University Hospital; Aarhus Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,9,3]]},"reference":[{"key":"10.1002\/pbc.24623-BIB0001|pbc24623-cit-0001","article-title":"Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia","author":"Pui","year":"2009","journal-title":"Leukemia"},{"key":"10.1002\/pbc.24623-BIB0002|pbc24623-cit-0002","article-title":"Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia","author":"Schmiegelow","year":"2009","journal-title":"Leukemia"},{"key":"10.1002\/pbc.24623-BIB0003|pbc24623-cit-0003","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2141.2009.07765.x","article-title":"Advances in individual prediction of methotrexate toxicity: A review","volume":"146","author":"Schmiegelow","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1002\/pbc.24623-BIB0004|pbc24623-cit-0004","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/028418698429586","article-title":"Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia-A logistic regression analysis","volume":"37","author":"Rask","year":"1998","journal-title":"Acta Oncol"},{"key":"10.1002\/pbc.24623-BIB0005|pbc24623-cit-0005","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1200\/JCO.1994.12.8.1667","article-title":"Patient characteristics associated with high-risk methotrexate concentrations and toxicity","volume":"12","author":"Relling","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24623-BIB0006|pbc24623-cit-0006","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1038\/sj.leu.2404404","article-title":"High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia","volume":"20","author":"Skarby","year":"2006","journal-title":"Leukemia"},{"key":"10.1002\/pbc.24623-BIB0007|pbc24623-cit-0007","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF00401438","article-title":"Theoretically required urinary flow during high-dose methotrexate infusion","volume":"13","author":"Sasaki","year":"1984","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1002\/pbc.24623-BIB0008|pbc24623-cit-0008","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s00280-002-0565-9","article-title":"Effects of sodium in hydration solution on plasma methotrexate concentrations following high-dose methotrexate in children with acute lymphoblastic leukemia","volume":"51","author":"Kinoshita","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1002\/pbc.24623-BIB0009|pbc24623-cit-0009","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1200\/JCO.1988.6.5.797","article-title":"Effect of hydration on methotrexate plasma concentrations in children with acute lymphocytic leukemia","volume":"6","author":"Christensen","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24623-BIB0010|pbc24623-cit-0010","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/BF00548590","article-title":"Effect of urine pH and flow on renal clearance of methotrexate","volume":"19","author":"Sand","year":"1981","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1002\/pbc.24623-BIB0011|pbc24623-cit-0011","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.2165\/00003088-200645120-00007","article-title":"Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia","volume":"45","author":"Aumente","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1002\/pbc.24623-BIB0012|pbc24623-cit-0012","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/pbc.20032","article-title":"High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: Lack of relation between serum methotrexate concentration and creatinine clearance","volume":"43","author":"Joannon","year":"2004","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.24623-BIB0013|pbc24623-cit-0013","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/BF00686226","article-title":"Proteinuria due to suboptimal hydration with high-dose methotrexate therapy","volume":"33","author":"Kovacs","year":"1993","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1002\/pbc.24623-BIB0014|pbc24623-cit-0014","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/j.1442-200X.2007.02461.x","article-title":"Successful high-dose methotrexate chemotherapy in a patient with acute lymphocytic leukemia who developed acute renal failure during the initial treatment","volume":"49","author":"Isoda","year":"2007","journal-title":"Pediatr Int"},{"key":"10.1002\/pbc.24623-BIB0015|pbc24623-cit-0015","volume-title":"Declaration of Helsinki: ethical principles for medical research involving human subjects","year":"2010"},{"key":"10.1002\/pbc.24623-BIB0016|pbc24623-cit-0016","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF00262416","article-title":"Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients","volume":"3","author":"Evans","year":"1979","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1002\/pbc.24623-BIB0017|pbc24623-cit-0017","first-page":"1665","article-title":"Pharmacokinetics of high-dose methotrexate with citrovorum factor rescue","volume":"61","author":"Isacoff","year":"1977","journal-title":"Cancer Treat Rep"},{"key":"10.1002\/pbc.24623-BIB0018|pbc24623-cit-0018","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJM197709222971203","article-title":"Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity","volume":"297","author":"Stoller","year":"1977","journal-title":"N Engl J Med"},{"key":"10.1002\/pbc.24623-BIB0019|pbc24623-cit-0019","first-page":"25","article-title":"Clinical pharmacology of high-dose methotrexate (NSC-740)","volume":"6","author":"Tattersall","year":"1975","journal-title":"Cancer Chemother Rep"},{"key":"10.1002\/pbc.24623-BIB0020|pbc24623-cit-0020","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1600-0609.2008.01128.x","article-title":"Influence of methylene tetrahydrofolate reductase polymorphisms and coadministration of antimetabolites on toxicity after high dose methotrexate","volume":"81","author":"van Kooten Niekerk","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1002\/pbc.24623-BIB0021|pbc24623-cit-0021","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00280-002-0552-1","article-title":"High-dose methotrexate: On the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL)","volume":"51","author":"Skarby","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1002\/pbc.24623-BIB0022|pbc24623-cit-0022","doi-asserted-by":"crossref","first-page":"5972","DOI":"10.1200\/JCO.2008.20.4156","article-title":"Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects","volume":"27","author":"Trevino","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24623-BIB0023|pbc24623-cit-0023","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.clpt.2006.08.012","article-title":"High-dose methotrexate in pediatric acute lymphoblastic leukemia: Impact of ABCC2 polymorphisms on plasma concentrations","volume":"80","author":"Rau","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1002\/pbc.24623-BIB0024|pbc24623-cit-0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/gr.129668.111","article-title":"Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition","volume":"22","author":"Ramsey","year":"2012","journal-title":"Genome Res"}],"container-title":["Pediatric Blood & Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.24623","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/pbc.24623","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T16:03:32Z","timestamp":1715961812000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.24623"}},"subtitle":["Prehydration for High-Dose Methotrexate"],"short-title":[],"issued":{"date-parts":[[2013,9,3]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"URL":"https:\/\/doi.org\/10.1002\/pbc.24623","archive":["Portico"],"relation":{},"ISSN":["1545-5009"],"issn-type":[{"value":"1545-5009","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9,3]]}}}